Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Shasun Buys Nuprin, DSM And GSK Earnings, Ad Claims Referred To FTC

This article was originally published in The Tan Sheet

Executive Summary

Shasun acquires ibuprofen products; DSM predicts nutrition sales will increase; GSK sales fall on supply chain trouble; Nature’s Medicine Associates’ ad referred to FTC; Heinrich co-sponsors designer steroid bill; and AHPA eases botanical identification burden.

You may also be interested in...



Hi-Tech CEO Wheat Arrested In FDA Investigation Of Steroid-Spiked Supplements

Hi-Tech Pharmaceuticals CEO Jared Wheat and an associate face 18 criminal charges in federal court alleging they falsified FDA documents and distributed as supplements products containing steroid ingredient. Wheat is appealing the indictment to federal circuit court.

Trump Administration May Relax Supplement Industry Oversight, But Heighten Trade Concerns

Supplement industry trade associations see positives in working with President-elect Trump, including his focus on business, but they also express concern with the possibility of restrictive trade prospects.

Alli Labels In U.S. Add Seizure Advisory Similar To E.U. Change

GSK also recently posted to the alli brand website statements on why language was added to the Drug Facts panel for the orlistat 60 mg product. FDA contacted Glaxo in November 2013 requesting a supplement NDA for the label change, FDA’s Division of Nonprescription Clinical Evaluation said.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel